Company news

Regenxbio Inc. news in 2022

Regenxbio Inc.'s news releases, calls and decks from 2022, newest first.

View company

REGENXBIO Reports Update on Advancement of Programs for CLN2 Disease

December 20, 2022

REGENXBIO Announces Completion of Dosing in the Phase I/II Trial of RGX-111 for the Treatment of Severe MPS I

December 7, 2022

REGENXBIO Reports Third Quarter 2022 Financial Results and Recent Operational Highlights

November 2, 2022

REGENXBIO Presents Positive Interim Data from and the Expansion of Phase II ALTITUDE® Trial of RGX-314 for the Treatment of Diabetic Retinopathy Using Suprachoroidal Delivery

November 2, 2022

REGENXBIO to Host Conference Call on November 3 to Discuss Third Quarter 2022 Financial Results, Recent Operational Highlights and Interim Data from Phase II ALTITUDE® Trial of RGX-314 for the Treatment of Diabetic Retinopathy

October 26, 2022

REGENXBIO Announces Additional Positive Interim Data from Trials of RGX-314 for the Treatment of Wet AMD

October 2, 2022

REGENXBIO Announces Presentation at Chardan's 6th Annual Genetic Medicines Conference

September 26, 2022

REGENXBIO Announces Upcoming Presentations During the American Academy of Ophthalmology 2022 Annual Meeting

September 25, 2022

REGENXBIO Presents Additional Positive Interim Data from the Phase I/II/III CAMPSIITE™ Trial of RGX-121 for the Treatment of MPS II (Hunter Syndrome) at the Society for the Study of Inborn Errors of Metabolism (SSIEM) Annual Symposium

August 30, 2022

REGENXBIO Announces Presentations at the Society for the Study of Inborn Errors of Metabolism Annual Symposium

August 22, 2022

REGENXBIO Announces Presentation at the H.C. Wainwright 2nd Annual Ophthalmology Virtual Conference

August 9, 2022

REGENXBIO Reports Second Quarter 2022 Financial Results and Recent Operational Highlights

August 2, 2022

REGENXBIO Announces Intention to File a Biologics License Application Using the Accelerated Approval Pathway for RGX-121, an AAV Therapeutic for the Treatment of MPS II

August 2, 2022

REGENXBIO to Host Conference Call on August 3 to Discuss Second Quarter 2022 Financial Results and Recent Operational Highlights

July 31, 2022

REGENXBIO Announces Enrollment Complete in Cohort 5 of Phase II AAVIATE® Trial

July 7, 2022

REGENXBIO Opens State-of-the-Art Gene Therapy Manufacturing Facility

June 8, 2022

Jennifer Zachary Joins REGENXBIO Board of Directors

June 6, 2022

REGENXBIO Reports First Quarter 2022 Financial Results and Recent Operational Highlights

May 3, 2022

REGENXBIO Announces Presentations at the American Society of Gene & Cell Therapy (ASGCT) 25th Annual Meeting

May 2, 2022

REGENXBIO to Host Conference Call on May 4 to Discuss First Quarter 2022 Financial Results and Recent Operational Highlights

April 26, 2022

REGENXBIO Announces Presentation at Chardan's 6th Annual Genetic Medicines and Cell Therapy Manufacturing Summit

April 19, 2022

REGENXBIO Reports Fourth Quarter and Full-Year 2021 Financial Results and Recent Operational Highlights

February 28, 2022

REGENXBIO to Host Conference Call on March 1 to Discuss Fourth Quarter and Full-Year 2021 Financial Results and Recent Operational Highlights

February 21, 2022

REGENXBIO Presents Positive Interim Data from Phase II ALTITUDE™ Trial of RGX-314 for the Treatment of Diabetic Retinopathy Using Suprachoroidal Delivery

February 11, 2022

REGENXBIO Presents Positive Initial Data from Phase I/II Trial of RGX-111 for the Treatment of Severe MPS I at 18th Annual WORLDSymposium™ 2022

February 8, 2022

REGENXBIO Presents Additional Positive Interim Data from Phase I/II Trial of RGX-121 for the Treatment of MPS II (Hunter Syndrome) at 18th Annual WORLDSymposium™ 2022

February 8, 2022

REGENXBIO Announces Presentations at the 11th Annual SVB Leerink Global Healthcare Conference

February 7, 2022

REGENXBIO Announces Presentations at the Angiogenesis, Exudation, and Degeneration 2022 Conference

February 3, 2022

REGENXBIO Announces Presentations at the 18th Annual WORLDSymposium™ 2022

January 30, 2022

REGENXBIO Announces Initiation of Second Pivotal Trial in RGX-314 Clinical Program for the Treatment of Wet AMD Using Subretinal Delivery

January 9, 2022

REGENXBIO Announces FDA Clearance of IND for Clinical Trial of RGX-202, a Novel Gene Therapy Candidate for Duchenne Muscular Dystrophy

January 5, 2022

Calls in 2022

Decks in 2022